Clinical Trial Search

Phase 3 N=795 A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Coronary Artery Disease

Primary: Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity — .719; .537 Proportion…

Lantheus Medical Imaging Results Apr 2016 2.5% serious AE View details

Phase 3 N=32 Effects of Intensive cART During Acute/Early HIV Infection

Acute HIV Infection

Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…

University of Toronto Results Apr 2016 3.1% serious AE View details

Phase 3 N=194 Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.

Chronic Obstructive Pulmonary Disease

Primary: Change From Baseline in Peak Inspiratory Capacity (IC) Comparison Between QVA149 and Placebo — 0.3790; 0.1769 Liters — p=<0.0001

Novartis Pharmaceuticals Results Apr 2016 1.6% serious AE View details

Phase 3 N=421 Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) — -0.17; -0.65; -0.93 percent — p=<0.001

Takeda Results Apr 2016 2.1% serious AE View details

Phase 3 N=102 A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

Muscle Soreness

Primary: Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW. — 50.15; 54.83 units on a scale (NRS)

Novartis Results Apr 2016 0.0% serious AE View details

Phase 3 N=2,672 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Breast Cancer

Primary: Disease-free Survival — 87.3; 91.1 percentage of participants — p=.0002

ETOP IBCSG Partners Foundation Results Apr 2016 37.2% serious AE View details

Phase 3 N=185 Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity

Xerostomia · Depression · Hypertension

Primary: Dry Mouth Questionnaire (DMQ) — 3.4; 1.4 units on a scale

Universidad de Granada Results Apr 2016 0.0% serious AE View details

Phase 3 N=955 Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial

Breast Augmentation · Breast Reconstruction · Breast Revision

Primary: 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation — 22.3; 52.7; 35.0; 59.7 percentage of subjects

Mentor Worldwide, LLC Results Apr 2016 2.0% serious AE View details

Phase 3 N=381 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement

Macular Edema

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…

Bayer Results Apr 2016 17.2% serious AE View details

Phase 3 N=709 Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

Primary: Change From Baseline of HbA1c After 24 Weeks of Treatment. — -0.53; -0.21; -0.58; -0.10 Percentage of HbA1c — p=0.0013

Boehringer Ingelheim Results Apr 2016 3.4% serious AE View details

Phase 3 N=4,040 Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

Rotavirus Gastroenteritis

Primary: Number of Participants With Any Severity of Rotavirus Gastroenteritis — 34; 109 Participants — p=<0.001

Merck Sharp & Dohme LLC Results Apr 2016 16.8% serious AE View details

Phase 3 N=140 A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia

Anemia

Primary: Percentage of Participants Maintaining Their Mean Hb Concentration Within Plus/Minus (±) 1 Grams Per Deciliter (g/dL) of the Reference Range and Between 10.0 and 12.0…

Hoffmann-La Roche Results Apr 2016 9.0% serious AE View details

Phase 3 N=79 Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

HIV · HBV

Primary: Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL — 100.0; 94.4 percentage of participants

Gilead Sciences Results Apr 2016 15.6% serious AE View details

Phase 3 N=103 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

Primary: Percentage of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Actual End of Treatment (EOT) — 83.5 Percentage of Participants

Janssen Infectious Diseases BVBA Results Apr 2016 4.9% serious AE View details

Phase 3 N=2,414 MK-0524B Lipid Study (MK-0524B-063)

Primary Hypercholesterolemia · Mixed Dyslipidemia

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change

Merck Sharp & Dohme LLC Results Apr 2016 1.0% serious AE View details